Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764098 · ClinicalTrials.gov registry record · Phase 2
Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders
A Phase 2 study of Alcohol Use, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT03764098: Recruiting Phase 2 study of Alcohol Use, sponsored by Yale University.
NCT03764098 is a Phase 2 study of Alcohol Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 160 participants, below the 263-participant average among 23 other Alcohol Use trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03764098, a Phase 2 study of Alcohol Use, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
For this protocol, the investigators plan to collect pilot data to examine sex differences in guanfacine's effect on 1) counteracting stress and stimulation based drinking behavior in the laboratory and 2) improving clinical outcomes during a subsequent treatment phase.
Primary Outcome
Means mls of alcohol consumed for guanfacine ER and placebo groups during 120 minute alcohol self administration sessions with personalized stress imagery vs stimulation imagery vs neutral imagery taking place as close to Week 0 of steady state as possible comparing females to males.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Guanfacine ER
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
What NCT03764098 shows while recruiting
NCT03764098 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 263-participant average among 23 other Alcohol Use trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Alcohol Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03764098 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03764098 about?
NCT03764098 is a clinical study titled "Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders". For this protocol, the investigators plan to collect pilot data to examine sex differences in guanfacine's effect on 1) counteracting stress and stimulation based drinking behavior in the laboratory and 2) improving clinical outcomes during a subsequent treatment phase.
What is the current status of trial NCT03764098?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-08-10. Estimated completion is 2026-08-31.
What conditions does trial NCT03764098 study?
This clinical trial studies the following conditions: Alcohol Use.
What interventions are being tested in trial NCT03764098?
The interventions under investigation include: Placebo (OTHER), Guanfacine ER (DRUG).
Who is sponsoring clinical trial NCT03764098?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03764098 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03764098's enrollment target sits among peer trials
160 10th of 23 higher than 14 of 23 other Alcohol Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxytocin, Alcohol Craving, and Intimate Partner Aggression
COMPLETED · Phase 2
-
ED Intervention to Reduce Risky Behaviors in Drivers
COMPLETED · Phase 2
-
Multi-Component Breath Alcohol Intervention Phase 3
RECRUITING · NA
-
Wellness, Alcohol, Vitals, and Emotions
RECRUITING · NA
-
Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment
RECRUITING · NA
-
Stress and Resilience
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI